Z

Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456

Watchlist Manager
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Watchlist
Price: 14.87 CNY -5.41% Market Closed
Market Cap: 13.4B CNY
Have any thoughts about
Zhejiang Jiuzhou Pharmaceutical Co Ltd?
Write Note

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Gross Profit
ÂĄ1.7B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
17%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Gross Profit
ÂĄ9.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Gross Profit
ÂĄ4.8B
CAGR 3-Years
13%
CAGR 5-Years
17%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Gross Profit
ÂĄ22.1B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Gross Profit
ÂĄ10.5B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Gross Profit
ÂĄ319.6m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View

Market Cap
13.4B CNY
Industry
Pharmaceuticals

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. engages in the production and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst and lithium battery materials. The company is headquartered in Taizhou, Zhejiang and currently employs 4,083 full-time employees. The company went IPO on 2014-10-10. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The firm mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The New Drug and Intermediates CDMO segment mainly provides services for innovative medicines of pre-clinical chemical manufacturing and controls (CMC), clinical phases I, II and III, new drug application (NDA) and various stages after going public. The Specialty API and Intermediates segments mainly provides services including patent breakthroughs, production process improvement, drug certificate declaration, and cGMP standard commercial production for patented expired or soon-to-be-expired drugs for global chemical and generic drug manufacturers.

Intrinsic Value
25.64 CNY
Undervaluation 42%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
1.7B CNY

Based on the financial report for Jun 30, 2024, Zhejiang Jiuzhou Pharmaceutical Co Ltd's Gross Profit amounts to 1.7B CNY.

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
17%

Over the last year, the Gross Profit growth was -15%. The average annual Gross Profit growth rates for Zhejiang Jiuzhou Pharmaceutical Co Ltd have been 15% over the past three years , 24% over the past five years , and 17% over the past ten years .

Back to Top